Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 148 is an isotonic crystalloid solution that provides electrolyte replacement and volume expansion. It mimics plasma electrolyte composition, with acetate and gluconate as bicarbonate precursors that are metabolized to bicarbonate in the liver and kidneys, helping to maintain acid-base balance.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Intravenous replacement of extracellular fluid losses,Maintenance of fluid and electrolyte balance,Correction of metabolic acidosis,Off-label: Resuscitation in hypovolemia, perioperative fluid management
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion; dose determined by electrolyte and fluid requirements. Typical adult rate: 25-100 m L/hour.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable; Plasma-Lyte 148 contains electrolytes and water that distribute according to body fluid compartments; infusion rate and renal function dictate elimination; clinical context: in normal renal function, excess fluids and electrolytes are cleared with a half-life of approximately 2-4 hours.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Acetate and gluconate are metabolized in the liver and kidneys to bicarbonate. Water and electrolytes are not metabolized but undergo renal excretion.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal: >90% of infused electrolytes and water are excreted unchanged in urine. Biliary/fecal excretion is negligible (<1%).
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Not applicable; individual electrolytes do not bind to plasma proteins (e.g., sodium, chloride, potassium, magnesium, acetate, gluconate have negligible protein binding).
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Not applicable as a single value; electrolytes distribute into total body water (approximately 0.6 L/kg in adults); clinical meaning: initial distribution reflects extracellular fluid expansion.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intravenous: 100% (directly into systemic circulation).
100% intravenous; not administered by other routes.
No specific dose adjustment; use with caution in renal impairment due to risk of electrolyte imbalances. Monitor serum electrolytes and renal function.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No specific adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Intravenous infusion; dose based on weight and clinical status. Typical rate: 5-20 m L/kg/hour, adjust based on response.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Use with caution due to potential for fluid overload and electrolyte disturbances; monitor renal function and adjust infusion rate accordingly.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None
Not applicable; no FDA boxed warning exists for this product.
Risk of fluid overload, especially in patients with heart failure or renal impairment,Electrolyte disturbances (hypernatremia, hyperkalemia, hypokalemia, hypercalcemia, hypermagnesemia) may occur,Monitor serum electrolytes, fluid balance, and renal function,Not recommended for use in patients with severe renal impairment or anuria,Use with caution in patients with metabolic alkalosis or conditions with predisposing factors for electrolyte imbalances
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hypersensitivity to any component,Severe renal impairment with oliguria or anuria,Hyperkalemia,Metabolic alkalosis,Clinically significant hypercalcemia,Patients with conditions where sodium retention is a concern (e.g., congestive heart failure, edema, cirrhosis)
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
None; PLASMA-LYTE 148 is administered intravenously and does not interact with food. However, patients with electrolyte imbalances may require dietary adjustments (e.g., low potassium or low sodium diet) as directed by their physician.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No fetal risks have been associated with Plasma-Lyte 148 in Water. It is an isotonic crystalloid solution containing electrolytes and water, lacking known teratogenic properties. No trimester-specific risks reported.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Plasma-Lyte 148 components are endogenous and normally present in breast milk. No specific M/P ratio available; expected to be safe during lactation with usual clinical monitoring.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
Pregnancy may increase total body water and electrolyte requirements; dose adjustments are generally not required but individualize based on maternal status and volume deficits.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
PLASMA-LYTE 148 is a balanced crystalloid solution with physiologic concentrations of electrolytes and p H 7.4. It is preferred over normal saline in patients with hyperchloremic metabolic acidosis or renal impairment. Avoid in patients with severe hyperkalemia, hypercalcemia, or metabolic alkalosis. Do not administer simultaneously with blood products through the same IV line due to risk of hemolysis from calcium content.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This solution is given intravenously to replace fluids and electrolytes.,Report any signs of allergic reaction like rash, itching, or difficulty breathing immediately.,Tell your healthcare provider if you have kidney disease, heart failure, or are on a low-sodium diet.,Inform your doctor if you are pregnant, breastfeeding, or taking any medications.,The infusion site should be monitored for redness, swelling, or pain.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 148 is an isotonic crystalloid solution that provides electrolyte replacement and volume expansion. It mimics plasma electrolyte composition, with acetate and gluconate as bicarbonate precursors that are metabolized to bicarbonate in the liver and kidneys, helping to maintain acid-base balance.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by electrolyte and fluid requirements. Typical adult rate: 25-100 m L/hour.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is classified as Category C. No fetal risks have been associated with Plasma-Lyte 148 in Water. It is an isotonic crystalloid solution containing electrolytes and water, lacking known teratogenic properties. N. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.